Loading cancer entity…
Loading cancer entity…
Clinical trials
3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (571)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03425461 | Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma | terminated | Phase 1 | 6 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Apr 2, 2021 | clinicaltrials |
| NCT02110355 | A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma | completed | Phase 1 | 31 | Kartos Therapeutics, Inc.INDUSTRY | 2 | Mar 26, 2021 | clinicaltrials |
| NCT00303251 | Safety of TKI258 in Advanced/Metastatic Melanoma Subjects | completed | Phase 1 / Phase 2 | 47 | Novartis PharmaceuticalsINDUSTRY | 1 | Mar 11, 2021 | clinicaltrials |
| NCT00258687 | Vaccine Trial for Clear Cell Sarcoma, Pediatric Renal Cell Carcinoma, Alveolar Soft Part Sarcoma and Children With Stage IV Melanoma | completed | Phase 1 | 12 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 3, 2021 | clinicaltrials |
| NCT00398450 | Azacitidine and Interferon Alfa in Treating Patients With Metastatic Melanoma | completed | Phase 1 | 12 | University of California, San DiegoOTHER | 1 | Mar 3, 2021 | clinicaltrials |
| NCT00961844 | Trial for Vaccine Therapy With Dendritic Cells in Patients With Metastatic Malignant Melanoma | terminated | Phase 1 / Phase 2 | 15 | Steinar AamdalOTHER | 1 | Feb 26, 2021 | clinicaltrials |
| NCT02897765 | A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer | completed | Phase 1 | 34 | BioNTech US Inc.INDUSTRY | 1 | Feb 25, 2021 | clinicaltrials |
| NCT02339324 | Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b | completed | Phase 1 | 31 | Yana NajjarOTHER | 1 | Feb 24, 2021 | clinicaltrials |
| NCT02902042 | Encorafenib + Binimetinib + Pembrolizumab in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma(IMMU-TARGET) | completed | Phase 1 / Phase 2 | 16 | Prof. Dr. med. Dirk SchadendorfOTHER | 1 | Feb 16, 2021 | clinicaltrials |
| NCT04756934 | A Study of HX008 Plus LP002 for the Treatment of Patients With Advanced Melanoma | unknown | Phase 1 | 63 | Taizhou HoudeAoke Biomedical Co., Ltd.INDUSTRY | 1 | Feb 16, 2021 | clinicaltrials |
| NCT04197882 | Clinical Study to Evaluate OrienX010 in Combination With Toripalimab as Neoadjuvant Treatment in Advanced Melanoma | unknown | Phase 1 | 33 | Peking University Cancer Hospital & InstituteOTHER | 1 | Feb 10, 2021 | clinicaltrials |
| NCT03747744 | Intratumoral Injection of Autologous CD1c (BDCA-1)+ Myeloid Dendritic Cells Plus Talimogene Laherparepvec (T-VEC)(myDCTV) | unknown | Phase 1 | 18 | Universitair Ziekenhuis BrusselOTHER | 1 | Dec 29, 2020 | clinicaltrials |
| NCT00304525 | A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma(CHIR-265-MEL01) | completed | Phase 1 / Phase 2 | 104 | Novartis PharmaceuticalsINDUSTRY | 2 | Dec 19, 2020 | clinicaltrials |
| NCT01430416 | Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients | completed | Phase 1 | 153 | Novartis PharmaceuticalsINDUSTRY | 4 | Dec 19, 2020 | clinicaltrials |
| NCT01562899 | A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors | terminated | Phase 1 / Phase 2 | 77 | PfizerINDUSTRY | 8 | Dec 10, 2020 | clinicaltrials |
| NCT03354962 | Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA) | terminated | Phase 1 / Phase 2 | 6 | Institut Claudius RegaudOTHER | 1 | Dec 4, 2020 | clinicaltrials |
| NCT01149343 | Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer | completed | Phase 1 | 107 | GlaxoSmithKlineINDUSTRY | 6 | Nov 20, 2020 | clinicaltrials |
| NCT01586403 | Transfer of Genetically Engineered Lymphocytes in Melanoma Patients | active not recruiting | Phase 1 | 14 | Loyola UniversityOTHER | 1 | Oct 30, 2020 | clinicaltrials |
| NCT03538028 | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | completed | Phase 1 | 22 | Incyte Biosciences International SàrlINDUSTRY | 1 | Oct 30, 2020 | clinicaltrials |
| NCT02012231 | Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers. | terminated | Phase 1 | 5 | Fore BiotherapeuticsINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT02709889 | Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 200 | AbbVieINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT03088176 | Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma | unknown | Phase 1 | 4 | West Cancer CenterOTHER | 1 | Oct 12, 2020 | clinicaltrials |
| NCT02771340 | Study Evaluating Single and Repeated Intravitreal Doses of ICON-1 in Patients With Uveal Melanoma | completed | Phase 1 | 10 | Iconic Therapeutics, Inc.INDUSTRY | 1 | Oct 1, 2020 | clinicaltrials |
| NCT03086174 | Tolerability and Pharmacokinetics of Toripalimab in Combination With Axitinib in Patients With Kidney Cancer and Melanoma | unknown | Phase 1 | 24 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Sep 30, 2020 | clinicaltrials |
| NCT02029690 | Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin(TRAP) | terminated | Phase 1 | 85 | Polaris GroupINDUSTRY | 2 | Sep 25, 2020 | clinicaltrials |
| NCT03957096 | A Safety Study of SGN-CD47M in Patients With Solid Tumors | terminated | Phase 1 | 16 | Seagen Inc.INDUSTRY | 1 | Sep 17, 2020 | clinicaltrials |
| NCT01801358 | A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma | terminated | Phase 1 / Phase 2 | 38 | Array Biopharma, now a wholly owned subsidiary of PfizerINDUSTRY | 6 | Sep 16, 2020 | clinicaltrials |
| NCT03597282 | A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma | terminated | Phase 1 | 22 | BioNTech US Inc.INDUSTRY | 1 | Sep 3, 2020 | clinicaltrials |
| NCT01590082 | Doxycycline, Temozolomide and Ipilimumab in Melanoma | terminated | Phase 1 / Phase 2 | 12 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 2, 2020 | clinicaltrials |
| NCT02346955 | Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001) | terminated | Phase 1 | 27 | Famewave Ltd.INDUSTRY | 2 | Aug 27, 2020 | clinicaltrials |
| NCT04021420 | Safety and Efficacy of Sonocloud Device Combined With Nivolumab in Brain Metastases From Patients With Melanoma(SONIMEL01) | unknown | Phase 1 / Phase 2 | 21 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Aug 20, 2020 | clinicaltrials |
| NCT01512251 | BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma | completed | Phase 1 / Phase 2 | 8 | University of California, San FranciscoOTHER | 1 | Aug 17, 2020 | clinicaltrials |
| NCT03158935 | The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial(ACTIVATE) | completed | Phase 1 | 8 | University Health Network, TorontoOTHER | 1 | Aug 14, 2020 | clinicaltrials |
| NCT01425008 | Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma | completed | Phase 1 | 149 | Millennium Pharmaceuticals, Inc.INDUSTRY | 2 | Aug 10, 2020 | clinicaltrials |
| NCT00005617 | Vaccine Therapy in Treating Patients With Stage IV or Relapsed Malignant Melanoma | completed | Phase 1 | — | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 3, 2020 | clinicaltrials |
| NCT00039325 | Vaccine Therapy in Treating Patients With Stage IV or Recurrent Malignant Melanoma | completed | Phase 1 / Phase 2 | 28 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 3, 2020 | clinicaltrials |
| NCT00090896 | CP-675,206 (CTLA4-Blocking Monoclonal Antibody) Combined With Dendritic Cell Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery | completed | Phase 1 | 18 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 3, 2020 | clinicaltrials |
| NCT01005472 | Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant Melanoma | completed | Phase 1 | 16 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 3, 2020 | clinicaltrials |
| NCT00498979 | Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers | completed | Phase 1 | 22 | Case Comprehensive Cancer CenterOTHER | 1 | Jul 24, 2020 | clinicaltrials |
| NCT01656642 | A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma | completed | Phase 1 | 67 | Genentech, Inc.INDUSTRY | 1 | Jul 21, 2020 | clinicaltrials |
| NCT03415126 | A Study of ASN007 in Patients With Advanced Solid Tumors | completed | Phase 1 | 49 | Asana BioSciencesINDUSTRY | 1 | Jul 9, 2020 | clinicaltrials |
| NCT01211262 | Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma | completed | Phase 1 | 84 | Immunocore LtdINDUSTRY | 2 | Jul 8, 2020 | clinicaltrials |
| NCT02823405 | X4P-001 and Pembrolizumab in Patients With Advanced Melanoma(X4P-001-MELA) | completed | Phase 1 | 16 | X4 PharmaceuticalsINDUSTRY | 1 | Jul 7, 2020 | clinicaltrials |
| NCT02387125 | Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1 | terminated | Phase 1 | 79 | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 1 | Jul 1, 2020 | clinicaltrials |
| NCT00003060 | Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Metastatic Melanoma | terminated | Phase 1 | 6 | Louisiana State University Health Sciences Center ShreveportOTHER | 1 | Jun 30, 2020 | clinicaltrials |
| NCT00112242 | Immunotherapy of Stage III/IV Melanoma Patients | completed | Phase 1 | 39 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Jun 18, 2020 | clinicaltrials |
| NCT01308294 | Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients(LAG-3/IMP321) | terminated | Phase 1 / Phase 2 | 16 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Jun 11, 2020 | clinicaltrials |
| NCT03480152 | Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer | terminated | Phase 1 / Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Jun 2, 2020 | clinicaltrials |
| NCT01897116 | A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma | completed | Phase 1 | 8 | Abramson Cancer Center at Penn MedicineOTHER | 1 | May 29, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Apr 2, 2021source: clinicaltrials